Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Myc proteins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
InactiveUS20080268533A1Process stabilityReduce phosphorylationArtificial cell constructsCell culture active agentsMyc proteinsBiological activation
The present invention provides methods for stabilizing pluripotent cells through the transcriptional activation of c-myc. Alternatively, the cells are stabilized through the transcriptional activation of c-myc, and the stabilization of c-myc protein levels. c-myc protein can be stabilized through the inhibition of GSK3β or through other components of the cellular machinery that impact on c-myc stability. The invention contemplates the stabilized pluripotent cells produced using the methods described herein. Methods for the identification of compounds that modulate the stabilization of pluripotent cells through modulating transcriptional activation of c-myc, stabilization of c-myc protein levels, and / or inhibition of GSK3β activity are also contemplated.
Owner:UNIV OF GEORGIA RES FOUND INC
ELISA (enzyme-linked immunosorbent assay) method for quickly testing C-Myc by using monoclonal antibody
The invention relates to an ELISA (enzyme-linked immunosorbent assay) method for quickly testing C-Myc by using a monoclonal antibody. According to the method, prokaryotic expression C-Myc protein is purified through protein purification technology; immune mouse spleen cells are performed cell fusion with SP2 / 0 myeloma cell, and a clone capable of stably secreting an antibody against C-myc IgG1 and a Cmyc IgM antibody clone are obtained based on ELISA screening and the subtype identification of subclone and monoclonal antibody Ig. A sandwich ELISA method and the two direct ELISA methods for quickly testing c-Myc are built by using an antibody against c-Myc IgG1 and an antibody against c-Myc Ig. With the method, a C-myc protein sample is accurately detected, the detected C-myc protein concentration range is 0.01-1000 pmol / L, and the detection limit is 0.01-0.05 pmol / L; the specificity and the sensitivity of C-Myc detection are greatly improved, the operation is simple, and the repeatability is high; and the method detects the expression level of C-Myc in tumor tissues, and provides experimental data for screening of malignant tumor.
Owner:DALIAN UNIV
Action mechanism and application of fangchinoline in resisting conjunctival melanoma
The invention relates to application of a compound fangchinoline with a tetrahydroisoquinoline parent nucleus in the aspect of resisting conjunctival melanoma and research on an action mechanism of the compound fangchinoline. Specifically, experiments show that fangchinoline directly targets far-end upstream binding protein 2 (FUBP2), so that gene expression of c-Myc protein is reduced, expression of key proteins RAD51 and BRCA1 of c-Myc downstream homologous recombination (HR) pathways is reduced, and the purpose of inhibiting tumor replication is achieved. The compound disclosed by the invention can be administrated together with cisplatin or olaparib to increase the anti-conjunctival melanoma drug effect and reduce the drug toxicity, so that the compound has a good clinical application prospect.
Owner:EAST CHINA UNIV OF SCI & TECH +1
Small molecule c-myc inhibitors
This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.
Owner:SORRENTO THERAPEUTICS INC +1
Tryphostin-analogs for the treatment of cell proliferative diseases
InactiveUS20100292229A1Improved pharmacological profileImprove effectivenessBiocideOrganic chemistrySignalling moleculesMyc proteins
The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and / or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Nanoparticle formulations
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Owner:TAIGA BIOTECH
Target gene mimitin of myc
A new diagnosis or treatment of cancer is provided. The present invention provides a protein Mimitin which is a target of a cancer gene myc protein, a variant thereof and a fragment thereof, as well as a polynucleotide molecule encoding them. An inhibitory substance of biological activity of the present invention, which is afforded by the binding of a polynucleotide molecule encoding a Mimitin protein and Myc provides a useful means for the diagnosis, prophylaxis or treatment of cancer.
Owner:KURUME UNIVERSITY
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
ActiveUS9228189B2Inhibition of translationReduce expressionSugar derivativesScreening processMyc proteinsIn vivo
Owner:GERON CORPORATION
CD105, esVEGR2 and MYC three-protein combined prediction esophageal squamous carcinoma patient prognosis kit
The invention aims at providing a reagent for detecting the interest protein expression condition in paraffin-embedded tissue. According to the technical scheme, a detection kit for evaluating prognosis information of an esophageal squamous carcinoma patient is provided. The kit comprises antibody primary antibody CD105 protein, esVEGFR2 protein and MYC protein antibodies for resisting three kinds of interest protein, and further comprises goat serum, 0.01M citrate restoration liquid, 3% H2O2, a Polymer enhancer, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating prognosis of the esophageal squamous carcinoma patient, and is simpler than international TNM staging and easy to carry out, the sensibility and specificity of the kit are both higher than those of TNM staging, and the kit is more suitable for esophageal squamous carcinoma prognosis evaluation of Chinese.
Owner:SHANTOU UNIV MEDICAL COLLEGE
Application of ELL as E3 ubiquitin ligase
ActiveCN105602910APrevent proliferationEfficient degradationPeptide/protein ingredientsBiological material analysisUbiquitin ligaseIn vitro study
The invention discloses application of ELL as an E3 ubiquitin ligase. The application of ELL protein or truncated protein of the ELL protein to at least one of 1-6: 1, a protein product for degrading c-Myc is prepared; 2, the ELL protein or the truncated protein of the ELL protein is used as the E3 ubiquitin ligase; 3, a product for inhibiting tumor cell proliferation is prepared; 4, a product for inhibiting tumorigenesis is prepared; 5, a product for identifying or assisting in identifying whether tissue to be detected is tumor tissue or not is prepared; 6, a product for identifying or assisting in identifying whether a patient to be detected is a tumor patient or not is prepared. The experiment proves that ELL is combined with c-Myc and induces c-Myc to be degraded through proteasome, in-vivo and in-vitro studies both indicate that the ELL has the characteristic of the E3 ubiquitin ligase, can inhibit tumor cell proliferation and tumorigenesis, can be used as a molecular marker for tumor clinical diagnosis, and can be used for preparing the medicine or a kit for inhibiting tumors and a kit for diagnosing the tumors as the novel E3 ubiquitin ligase of c-Myc.
Owner:INST OF AQUATIC LIFE ACAD SINICA
Hepatocytes
InactiveUS20080131404A1Evaluate suitabilityDetermining effectBiocideFusion with DNA-binding domainOestrogen receptorMammal
The invention relates to the production of hepatocyte cell lines useful in toxicology screens or therapy. A mammalian hepatocyte comprises, as a single polypeptide, a fusion protein comprising a c-myc protein and an oestrogen receptor, or functional fragments thereof.
Owner:JOHNSON DEBORAH +3
Fluorescence spectrometry method for oncogene C-myc protein
InactiveCN101893573AEasy to operateImprove general performanceBiological testingFluorescence/phosphorescenceFluorescence spectrometryMyc proteins
The invention discloses a fluorescence spectrometry method for an oncogene C-myc protein. In the method, the determination basis is that the C-myc protein has fluorescence and has a fluorescence quenching phenomenon after combining with gold nano-sol; and the fluorescence quenching intensity (delta F) and the concentration change of the C-myc protein are in a linear corresponding relationship so as to fulfill the aim of determining the C-myc content. A C-myc protein sample is determined accurately by the method, the recovery rate of the C-myc is between 94.29 and 107.14 percent; the detectable C-myc protein concentration range is between 0 and 1,000 pmol / L; the linear range is between 87.5 and 875 pmol / L and between 0.175 and 17.5 pmol / L; and the detection limit is between 0.01 and 0.08 pmol / L. The determination method of the invention has the advantages of simple and convenient operation, wide linear range, high sensitivity, low detection limit, high stability and reproducibility and the like.
Owner:CHANGSHA UNIVERSITY OF SCIENCE AND TECHNOLOGY
Application of combination of N-Myc inhibiting agent and Olaparib to preparation of medicine for treating prostatic cancer
InactiveCN107929740AGrowth inhibitionInhibition of transplantation tumor formation efficiencyOrganic active ingredientsAntineoplastic agentsCancer geneMyc proteins
The invention relates to the technical field of medicine. In recent years, cancer genes MYCN (coding N-Myc protein) and signal channels thereof receive more attention in the tumor prevention and treatment and study field. The invention provides application of an N-Myc inhibiting agent to preparation of medicine for treating prostatic cancer, and particularly relates to the application of the combination of N-Myc inhibiting agent and Olaparib to effective inhibition of prostatic cancer (particularly to the growth of castration-resistant prostate cancer). The development of the prostatic canceris reduced; the clinic use and popularization are easy.
Owner:SHANGHAI CHANGHAI HOSPITAL
Plant expression plasmid vector containing C-Myc protein fusion label and construction method for vector
InactiveCN108893487AGuaranteed accuracyShort cycle timeVector-based foreign material introductionProtein targetRestriction enzyme digestion
The invention discloses a plant expression plasmid vector containing a C-Myc protein fusion label. The plant expression plasmid vector contains the C-Myc protein fusion label at a terminal C of the plant expression plasmid vector. The construction method for the plasmid vector comprises the following steps: (1) taking pCAMBIA1302 as a departing plasmid, carrying out restriction enzyme digestion onthe plasmid by using SpeI and Eco065I, and recycling a klenow fragment through electrophoretic gel cutting; (2) carrying out full-sequence synthesis on a nucleotide sequence encoded with three C-Mycproteins; (3) designing an amplification primer; and (4) adding a SpeI restriction enzyme cutting site at a terminal N, and adding an Eco065I restriction enzyme cutting site at the terminal C; carrying out restriction enzyme digestion on the synthesized fragment by using SpeI and Eco065I; and finally connecting products, transforming DH5 alpha by heat shock, and carrying out PCR identification toobtain positive clone. The plant expression plasmid vector has the advantages that the plant expression plasmid vector of a fusion label of small protein is obtained, a user is assisted to rapidly research functions of the protein, functions of the target protein cannot be interfered, and it ensures that the functions of the protein can be researched accurately.
Owner:INST OF ANIMAL SCI OF CHINESE ACAD OF AGRI SCI
Cancer associated gene mina 53, protein mina 53 and monoclonal antibody thereof
InactiveUS20060234318A1Prevent proliferationAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsTranscription initiation siteFhit gene
Myc protein is an unevenly distributed intermediate agent for cell proliferation, and activates a gene expression via E.box. Mina 53 gene encodes a protein of 53 kDa molecular weight and is present in the nucleoplasm and nucleolus. Mina 53 mRNA and protein expression are induced by artificial introduction of c-Myc activity. E.box site is present in the vicinity of the transcription initiation site of mina 53 gene, and the expression from mina 53 promoter is activated by the c-Myc through the medium of E.box. Specific inhibition of the mina 53 expression in HeLa cells and rat fibroblast cells 3Y1 having high expression c.myc strikingly inhibited the cell proliferation. Combination of these results shows that the mina 53 is a Myc target gene and is associated with the cell proliferation of mammal.
Owner:GAKKOUHOUJIN KURUME UNIV
Mycer immortalized hepatocyte
InactiveCN101044236AExcellent transplantFusion with DNA-binding domainAntipyreticOestrogen receptorMammal
Owner:RENEURON LTD
C-Myc protein combinable DNA (Deoxyribonucleic Acid) segment and application thereof to c-Myc activity detection
ActiveCN107460192AAccurate analysisMicrobiological testing/measurementVector-based foreign material introductionADAMTS ProteinsDNA fragmentation
The invention relates to a c-Myc protein combinable DNA (Deoxyribonucleic Acid) segment. The c-Myc protein combinable DNA segment comprises one or more c-Myc protein combining frames, wherein the sequence of each c-Myc protein combining frame is 5'-SCACGTGS-3' and S represents C or G; the invention further relates application of the DNA segment; the invention further relates to a method for detecting transcriptional regulation activity of c-Myc protein in cells. By utilizing the DNA segment and the method, provided by the invention, the transcriptional regulation activity of the c-Myc protein in the cells can be directly and specifically detected and the content of transcripts or the protein is also detected, so that the effect of the c-Myc protein, which is used as a transcription factor, in development of certain diseases can be more accurately analyzed.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
MYC cancer gene inhibition polypeptide and application thereof
InactiveCN106749549APrevent proliferationInhibition of telomerase activityPeptide/protein ingredientsDepsipeptidesTelomeraseFhit gene
The invention relates to the field of medicines, and in particular relates to polypeptide which can inhibit MYC carcinogenic protein and treat tumor. The sequence of the polypeptide is as shown in SEQ ID NO.1. The polypeptide has the application of tumor treatment. The application includes tumor treatment in multiple administration modes, including subcutaneous or intramuscular injection, intravenous injection or intravenous drip, and the like. The polypeptide has the beneficial effects that in-vitro proliferation activity of multiple tumor cells can be inhibited, MYC protein expression in tumor cells can be promoted, telomerase activity of a tumor cell can be inhibited, growth of tumor inside tumor model naked mice can be inhibited, and the survival rate of tumor-bearing mice can be increased. An effect of treating tumor can be achieved.
Owner:罗瑞雪
C-Myc protein inhibitor as well as preparation method and application thereof
PendingCN114437119AThe synthesis method is simpleEnhanced inhibitory effectBoron compound active ingredientsAntiviralsDiseaseMyc proteins
The invention relates to a c-Myc protein inhibitor as well as a preparation method and application thereof, the c-Myc protein inhibitor can selectively inhibit c-Myc protein, so that the c-Myc protein inhibitor can be used for preventing and treating c-Myc protein disorder related diseases, such as cancer, cardiovascular and cerebrovascular diseases, virus infection related diseases and the like.
Owner:SUZHOU KINTOR PHARMA
Application of amaranthus caudatus crude polysaccharide in preparation of anti-hepatoma drugs
PendingCN114432336AInhibit apoptosisCytotoxicOrganic active ingredientsAntineoplastic agentsCyclin D1Cancer cell
The invention discloses an application of crude amaranthus caudatus polysaccharide in preparation of anti-liver cancer drugs. According to the research of the invention, the amaranthus caudatus crude polysaccharide can obviously inhibit liver cancer cells and / or promote apoptosis of the liver cancer cells, has a cytotoxic effect on the liver cancer cells, causes the rise of ROS and MDA contents of the liver cancer cells, and reduces the levels of GSH and CAT; the amaranthus caudatus crude polysaccharide is used for down-regulating Nrf2 protein, up-regulating p-p38, p-ERK and p-JNK protein, retarding cell cycle Cyclin D1 and c-Myc protein, changing mitochondrial membrane permeability and inducing apoptosis of liver cancer cells through ROS (reactive oxygen species); no toxic effect is caused on human normal cells; therefore, the compound has a very good application value in the aspect of preparing anti-hepatoma drugs.
Owner:SOUTH CHINA AGRI UNIV
Cancer associated gene mina 53, protein Mina 53 and monoclonal antibody thereof
Owner:GAKKOUHOUJIN KURUME UNIV
Use of Ell as an E3 ubiquitin ligase
ActiveCN105602910BPrevent proliferationEfficient degradationPeptide/protein ingredientsBiological material analysisUbiquitin ligaseIn vitro study
Owner:INST OF AQUATIC LIFE ACAD SINICA
In Vitro and in vivo silencing of human c-myc oncogene expression by poly-DNP-RNA
InactiveUS20060122140A1High efficacyHigh sequence specificityGenetic material ingredientsIn-vivo testing preparationsIn vivoC myc oncogene
The present invention provides antisense oligoribonucleotides with sequences that recognize and bind to the c-myc gene or c-myc mRNA, where one or more sugar residues of the oligoribonucleotides are modified by the substitution of DNP at the 2′-O position. The antisense oligoribonucleotides can be used for inhibiting the growth of cells in which the c-myc gene is overexpressed by down-regulation of transcription of c-myc RNA or translation of the c-myc protein. The antisense oligoribonucleotides can also be used for diagnostic purposes to identify the overexpression of the c-myc gene. The nucleotide sequence of the DNP-oligoribonucleotides is complementary to the sequence 578 to 598 in c-myc mRNA and does not contain a G-quartet motif. This DNP-RNA can silence c-myc gene expression both in vitro and in vivo with high efficacy and sequence specificity.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
InactiveUS7241581B2Peptide/protein ingredientsBiological material analysisIl 4 receptorSurrogate analyte
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
Owner:RIGEL PHARMA
Application of pyrrolidin-2-one compounds in the preparation of drugs related to multiple myeloma
ActiveCN112190581BStrong inhibitory activityEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryEnzyme inhibitionPyrrolidinones
The invention relates to the application of a class of pyrrolidin-2-ketone compounds in the preparation of drugs related to multiple myeloma, which belongs to the field of medicinal chemistry and pharmacotherapy. The compounds have obvious enzyme inhibitory effect on c-Myc protein. The compound represented by formula I provided by the present invention, isomers or pharmaceutically acceptable salts thereof can be used in the preparation of drugs related to multiple myeloma.
Owner:XUZHOU MEDICAL UNIV
CD105, esvegr2 and myc triple protein joint prediction kit for the prognosis of patients with esophageal squamous cell carcinoma
The invention aims at providing a reagent for detecting the interest protein expression condition in paraffin-embedded tissue. According to the technical scheme, a detection kit for evaluating prognosis information of an esophageal squamous carcinoma patient is provided. The kit comprises antibody primary antibody CD105 protein, esVEGFR2 protein and MYC protein antibodies for resisting three kinds of interest protein, and further comprises goat serum, 0.01M citrate restoration liquid, 3% H2O2, a Polymer enhancer, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating prognosis of the esophageal squamous carcinoma patient, and is simpler than international TNM staging and easy to carry out, the sensibility and specificity of the kit are both higher than those of TNM staging, and the kit is more suitable for esophageal squamous carcinoma prognosis evaluation of Chinese.
Owner:SHANTOU UNIV MEDICAL COLLEGE
Markers for evaluating risk of familial breast cancer and application thereof
InactiveCN109182523AEarly detectionEasy to detectMicrobiological testing/measurementBiological material analysisFamilial breast cancerMyc proteins
The invention discloses a marker for evaluating the risk of familial breast cancer, which is MYC gene or MYC protein, and further confirms that the expression of MYC is up-regulated in a breast cancersample. The molecular marker can be used to prepare early diagnosis reagent or kit for familial breast cancer, which can detect the occurrence and development trend of breast cancer in the high-riskpopulation of breast cancer earlier and more conveniently. At the same time, the molecular marker can be used to detect breast cancer and provide therapeutic targets and important basis for gene therapy, drug therapy and other clinical applications.
Owner:北京致成生物医学科技有限公司
Polypeptide or derivatives thereof and application of polypeptide or derivatives thereof in preparation of medicines for preventing and treating tumors
Owner:BEIJING WEIFENG YIMIN TECH
Nanoparticle formulations
The invention relates to nanoparticle formulations. This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Owner:TAIGA BIOTECH
Immortalization of Splenic and Peripheral Blood Macrophages Using a Multi-Cistronic V-RAF/V-MYC Lentivirus
PendingUS20210017540A1Easy to useIncrease virus yieldVectorsBiological material analysisViral vectorSpleen
Vectors and methods are disclosed for immortalizing mammalian cells by co-expression of v-raf and v-myc proteins. A replication-defective viral vector is used for improved safety. The vector comprises an optional marker gene, and is especially useful for producing an immortalized macrophage by a method that involves contacting the vector with a monocyte, proliferatively growing the monocyte, growing the monocytic cell on a solid surface, and then growing the monocytic cell on a porous surface. An immortalized macrophage is also disclosed.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com